COACH Trial Data Show Accelerated Growth Benefits

New data from Week 52 of the ongoing COACH trial indicate that TransCon® hGH accelerated the benefits of TransCon® CNP beyond linear growth in children with achondroplasia. The combination therapy demonstrated unprecedented improvements in arm span, a significant measure for patients with this condition. These findings suggest a more comprehensive positive impact on growth and development than previously observed. The results represent a potential breakthrough in treating achondroplasia, offering enhanced therapeutic outcomes.